CF PHARMTECH (02652) announced on November 25, 2025, that its board of directors has reviewed and approved a proposal to convert 107 million non-tradable domestic shares held by 20 shareholders into H shares. These shares represent approximately 26.1% of the company's total issued share capital as of the announcement date. The number of non-tradable domestic shares applying for full H-share circulation is subject to filing with the China Securities Regulatory Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments